索非布韦联合达卡他韦治疗慢性丙型肝炎的临床效果观察

Clinical effect observation of Sofosbuvir combined with Daclatasvir in treatment of chronic hepatitis C

目的:观察索非布韦联合达卡他韦治疗慢性丙型肝炎(CHC)的临床效果。方法:收集70例CHC患者作为研究对象,按入院奇偶顺序分为观察组与对照组,每组35例。对照组给予聚乙二醇干扰素α-2a联合利巴韦林治疗,观察组给予索非布韦联合达卡他韦治疗,比较两组治疗效果及不良反应情况。结果:两组治疗后病毒应答率均随时间延长而逐渐升高,且观察组EVR率为94.29%、ETVR率为97.14%,均明显高于对照组的77.14%、82.86%(P<0.05)。治疗前,两组肝功能指标ALT、AST、ALB、TBIL水平比较,差异无统计学意义(P>0.05),治疗12周后,两组肝功能指标均明显改善(P<0.05),且观察组ALT、AST、TBIL的下调及ALB的上调程度均明显高于对照组(P<0.05)。观察组不良反应发生率为8.57%,明显低于对照组的34.29%(P<0.05)。结论:索非布韦联合达卡他韦治疗慢性丙型肝炎的临床效果及安全性优于聚乙二醇干扰素α-2a联合利巴韦林治疗。

Objective： To observe clinical effects of Sofosbuvir combined with Daclatasvir in treatment of chronic hepatitis C（CHC）. Methods： Seventy patients with CHC were selected as observation subjects and divided into observation group and control group according to the numerical parity method,with 35 cases in each group. The control group was treated with Peginterferon alfa-2 a plus Ribavirin,while the observation group was given Sofosbuvir combined with Daclatasvir. The therapeutic effects and side effects were observed and compared between the two groups. Results： The response rate of virus in both groups increased gradually with the prolongation of time after the treatment. The EVR rate in the observation group was 94. 29% and the ETVR rate was 97. 14%,which were significantly higher than those in the control group of 77.14% and 82.86%（P〈0.05）. Before the treatment,there were no significant differences in the ALT,AST,ALB and TBIL levels between the two groups（P〉0.05）. 12 weeks after the treatment,the indexes of liver function in both groups were significantly improved（P〈0.05）,and the ALT,AST,and TBIL levels were down regulated in the observation group and ALB was up regulated,and the regulation degrees were significantly higher than those in the control group（P〈0.05）. The incidence of adverse reactions in the observation group was 8.57%,which was significantly lower than that in the control group of 34. 29%（P〈0. 05）. Conclusions： Sofosbuvir combined with Daclatasvir in the treatment of CHC is more effective than Peginterferon alfa-2 a plus Ribavirin.